Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope

Abstract The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: “humans are nearing the f...

Full description

Bibliographic Details
Main Authors: Xinyu Lou, Zhichao Chen, Zhonggui He, Mengchi Sun, Jin Sun
Format: Article
Language:English
Published: SpringerOpen 2021-01-01
Series:Nano-Micro Letters
Subjects:
Online Access:https://doi.org/10.1007/s40820-020-00560-9
id doaj-598f1b8e4729481fbf615270962dfdc5
record_format Article
spelling doaj-598f1b8e4729481fbf615270962dfdc52021-01-10T12:56:43ZengSpringerOpenNano-Micro Letters2311-67062150-55512021-01-0113112610.1007/s40820-020-00560-9Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big HopeXinyu Lou0Zhichao Chen1Zhonggui He2Mengchi Sun3Jin Sun4Wuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityWuya College of Innovation, Shenyang Pharmaceutical UniversityAbstract The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: “humans are nearing the first commercial live bacteria therapeutic.” However, the facultative anaerobe Salmonella typhimurium VNP20009, which is particularly safe and shows anticancer effects in preclinical studies, had failed in a phase I clinical trial due to low tumor regression and undesired dose-dependent side effects. This is almost certain to disappoint people’s inflated expectations, but it is noted that recent state-of-the-art research has turned attention to bacteria-mediated synergistic cancer therapy (BMSCT). In this review, the foundation of bacteria-mediated bio-therapy is outlined. Then, we summarize the potential benefits and challenges of bacterial bio-therapy in combination with different traditional anticancer therapeutic modalities (chemotherapy, photothermal therapy, reactive oxygen and nitrogen species therapy, immunotherapy, or prodrug-activating therapy) in the past 5 years. Next, we discuss multiple administration routes of BMSCT, highlighting potentiated antitumor responses and avoidance of potential side effects. Finally, we envision the opportunities and challenges for BMSCT development, with the purpose of inspiring medicinal scientists to widely utilize the microbiome approach in patient populations.https://doi.org/10.1007/s40820-020-00560-9Bacteria-mediated synergistic cancer therapyMultiple administration routesAntitumor responsesPotential side effectsMicrobiome approach
collection DOAJ
language English
format Article
sources DOAJ
author Xinyu Lou
Zhichao Chen
Zhonggui He
Mengchi Sun
Jin Sun
spellingShingle Xinyu Lou
Zhichao Chen
Zhonggui He
Mengchi Sun
Jin Sun
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
Nano-Micro Letters
Bacteria-mediated synergistic cancer therapy
Multiple administration routes
Antitumor responses
Potential side effects
Microbiome approach
author_facet Xinyu Lou
Zhichao Chen
Zhonggui He
Mengchi Sun
Jin Sun
author_sort Xinyu Lou
title Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
title_short Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
title_full Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
title_fullStr Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
title_full_unstemmed Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
title_sort bacteria-mediated synergistic cancer therapy: small microbiome has a big hope
publisher SpringerOpen
series Nano-Micro Letters
issn 2311-6706
2150-5551
publishDate 2021-01-01
description Abstract The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: “humans are nearing the first commercial live bacteria therapeutic.” However, the facultative anaerobe Salmonella typhimurium VNP20009, which is particularly safe and shows anticancer effects in preclinical studies, had failed in a phase I clinical trial due to low tumor regression and undesired dose-dependent side effects. This is almost certain to disappoint people’s inflated expectations, but it is noted that recent state-of-the-art research has turned attention to bacteria-mediated synergistic cancer therapy (BMSCT). In this review, the foundation of bacteria-mediated bio-therapy is outlined. Then, we summarize the potential benefits and challenges of bacterial bio-therapy in combination with different traditional anticancer therapeutic modalities (chemotherapy, photothermal therapy, reactive oxygen and nitrogen species therapy, immunotherapy, or prodrug-activating therapy) in the past 5 years. Next, we discuss multiple administration routes of BMSCT, highlighting potentiated antitumor responses and avoidance of potential side effects. Finally, we envision the opportunities and challenges for BMSCT development, with the purpose of inspiring medicinal scientists to widely utilize the microbiome approach in patient populations.
topic Bacteria-mediated synergistic cancer therapy
Multiple administration routes
Antitumor responses
Potential side effects
Microbiome approach
url https://doi.org/10.1007/s40820-020-00560-9
work_keys_str_mv AT xinyulou bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope
AT zhichaochen bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope
AT zhongguihe bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope
AT mengchisun bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope
AT jinsun bacteriamediatedsynergisticcancertherapysmallmicrobiomehasabighope
_version_ 1724341972217364480